Development and validation of a stability indicating HPLC method for simultaneous determination of four novel fluoroquinolone dimers as potential antibacterial agents.

J Pharm Biomed Anal

Analytical Development, Aptuit Laurus Private Limited, ICICI Knowledge Park, Turkapally, Shameerpet, Hyderabad, Andhra Pradesh 500078, India.

Published: February 2012

A series of novel 6-fluoro1,4-dihydro-4-oxo-3-quinoline carboxylic acid dimers were synthesized as potential antibacterial agents from commercially available substituted fluorobenzoic acids. A stability indicating HPLC method was developed to determine these novel fluoroquinolone dimers using a systematic method development approach. Samples were subjected to stress conditions of hydrolysis, oxidation, photolysis and thermal degradation; and analyzed to demonstrate the specificity and stability indicating ability of the developed method. The precision for all four fluoroquinolone dimers was within 2.0% RSD. Calibration curves were linear (LOQ, 150%), with regression coefficients >0.99 for all dimers. The method was conveniently applied for determining purity and assay of these four novel fluoroquinolone dimers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2011.09.025DOI Listing

Publication Analysis

Top Keywords

fluoroquinolone dimers
16
stability indicating
12
novel fluoroquinolone
12
indicating hplc
8
hplc method
8
potential antibacterial
8
antibacterial agents
8
dimers
6
method
5
development validation
4

Similar Publications

Psittacosis Pneumonia Features, Distinguishing Characteristics, and Outcomes: A Retrospective Study.

Infect Drug Resist

December 2024

Department of Infectious Diseases, Shaoxing People's Hospital, Shaoxing, Zhejiang, People's Republic of China.

Purpose: Psittacosis is an often-neglected cause of community acquired pneumonia (CAP). The limited diagnostic methods for psittacosis pneumonia invariably result in an unfavourable prognosis. Consequently, the early detection of psittacosis pneumonia is crucial.

View Article and Find Full Text PDF

Structural basis of chiral wrap and T-segment capture by DNA gyrase.

Proc Natl Acad Sci U S A

December 2024

Department of Molecular Microbiology, John Innes Centre, Norwich NR4 7UH, United Kingdom.

Type II topoisomerase DNA gyrase transduces the energy of ATP hydrolysis into the negative supercoiling of DNA. The postulated catalytic mechanism involves stabilization of a chiral DNA loop followed by the passage of the T-segment through the temporarily cleaved G-segment resulting in sign inversion. The molecular basis for this is poorly understood as the chiral loop has never been directly observed.

View Article and Find Full Text PDF

There remains a clinical need for better approaches to rapid drug susceptibility testing in view of the increasing burden of multidrug resistant tuberculosis. Binary susceptibility phenotypes only capture changes in minimum inhibitory concentration when these cross the critical concentration, even though other changes may be clinically relevant. We developed a machine learning system to predict minimum inhibitory concentration from unassembled whole-genome sequencing data for 13 anti-tuberculosis drugs.

View Article and Find Full Text PDF

Rapid, DNA-induced interface swapping by DNA gyrase.

Elife

June 2024

Department Biochemistry & Metabolism, John Innes Centre, Norwich Research Park, Norwich, United Kingdom.

Article Synopsis
  • DNA gyrase is a bacterial enzyme made of two GyrA and two GyrB subunits, crucial for introducing negative supercoiling into DNA, which is important for replication and transcription.
  • The enzyme can swap its DNA-cleaving interfaces between two active units rapidly, a process facilitated by bending and wrapping DNA, along with the presence of excess GyrB.
  • This interface swapping occurs without ATP and suggests a new mechanism for DNA processing by gyrase, challenging previous models of how this enzyme functions.
View Article and Find Full Text PDF

The rise of multidrug-resistant (MDR) Gram-negative bacteria is a major global health problem necessitating the discovery of new classes of antibiotics. Novel bacterial topoisomerase inhibitors (NBTIs) target the clinically validated bacterial type II topoisomerases with a distinct binding site and mechanism of action to fluoroquinolone antibiotics, thus avoiding cross-resistance to this drug class. Here we report the discovery of a series of NBTIs incorporating a novel indane DNA binding moiety.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!